

Antibody–Drug Conjugates

Partner

SCIE

Co-sponsor THE SCIENCE OF WHAT'S POSSIBLE."

Antibody–drug conjugates (ADCs) are dynamic, heterogeneous mixtures typically comprising a cytotoxic drug covalently bound to an antibody via a synthetic linker. There is huge interest in ADCs as they have the potential to substantially improve efficacy and reduce toxicity compared with cytotoxic drugs. This interest is highlighted by a robust pipeline of ADCs in pre-clinical and clinical development. The heterogeneity and dynamic nature of ADCs raises unique bioanalytical challenges. During this Spotlight we have been exploring the analysis of ADCs and how these challenges are being addressed.



ADC bioanalysis in your laboratory



Is it better to develop bioanalytical strategies

for ADCs on a case-by-case basis?



Read more commentary and analysis on ADCs

Register for the panel discussion

Make sure you don't miss our next Spotlight